A molecular-targeted medical care can before long be offered
to advanced female internal reproductive organ cancer patients, prof Thomas
Jobling , chairman of the OCRF and medicine specialist, says. “If the patient
has had surgery to get rid of the growth however the result has been
sub-optimal, this will be offered. Tumours want new blood vessels to grow, and
this sort of drug stops that taking place.”
No comments:
Post a Comment